NOXXON Announces Initiation Of First-in-Human Clinical Trial With Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12. NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months.
[Read the full article here]Related News:
Fate Therapeutics Announces First Patient Treated In Phase 1b Clinical Trial Of FT1050 For Hematopoietic Stem Cell …
Fate Therapeutics Announces First Patient Treated In Phase 1b Clinical Trial Of FT1050 For Hematopoietic Stem Cell Support
Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial